论文部分内容阅读
美国生物技术总公司首先开始对其人超氧化物歧化酶(h SOD)进行Ⅰ期临床试验,用于治疗早产儿支气管肺发育不良(BPD),SOD 为破坏氧自由基的酶。早产儿缺乏h SOD,其肺易受氧自由基的损害,为使伴有呼吸窘迫的婴儿在保温箱内存活,需要高浓度氧环境,然而,当氧环境含有高水平氧自由基,其可使婴儿肺脏产生不可逆的疤痕组织,并导致慢性肺疾病BPD。对牛SOD的研究已经表明,此酶可降低由这种自由基造成的肺损伤。美国每年出生的25万早产儿中,4万患有呼吸窘迫综合征(RDS),其中20～30%发展为BPD,如
The American Biotech Corporation first started Phase I clinical trials of its human superoxide dismutase (h SOD) for the treatment of bronchopulmonary dysplasia (BPD) in preterm infants. SOD is an enzyme that destroys oxygen free radicals. Premature babies lack h SOD and their lungs are vulnerable to oxygen free radicals. High concentrations of oxygen are required to keep infants with respiratory distress in the incubator. However, when the oxygen environment contains high levels of oxygen free radicals, Causes irreversible scar tissue in infant lungs and leads to chronic lung disease BPD. Studies on bovine SOD have shown that this enzyme can reduce lung injury caused by such free radicals. Of the 250,000 preterm babies born each year in the United States, 40,000 have respiratory distress syndrome (RDS), of which 20 to 30% develop BPD